M-M-RII (measles, mumps, and rubella virus vaccine live) / Merck (MSD) - LARVOL DELTA

CORAL: Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (clinicaltrials.gov) - P3 | N=2226 | Terminated | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Terminated; Sponsor decision

Trial termination • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Drug Development. (PubMed, Alzheimers Dement) - "Our analysis demonstrated the utility of confirmatory scales to screen fail subjects lacking objectifiable cognitive decline. Depending on the instrument used, between a quarter and a third of subjects were deemed not eligible. However, substantial differences in performance between the instruments used were identified, especially in potential study participants with MMSE scores of 26 or below. While the FCSRT and WMS-LMII performed in an almost linear manner over the tested MMSE range, the RBANS performed in a curvilinear manner. Additionally, for those with MMSE scores below 25, the RBANS only identified a small subset of subjects as ineligible. Those weighing implementation of these instruments in a clinical trial should consider the presented data in the context of the MMSE inclusion criteria, subject and rater burden, and the goals of the trial."

Journal • Alzheimer's Disease • CNS Disorders

Biomarkers. (PubMed, Alzheimers Dement) - "Remarkably, substituting proper name delayed recall for logical memory total score improves sensitivity for tracking longitudinal cognitive decline related to AD blood-biomarker p-Tau217 group. Our study highlights a novel language measure that yielded composites more sensitive to AD-related preclinical changes. Follow-up analyses will investigate implications for screening and clinical trials."

Biomarker • Journal • Alzheimer's Disease • CNS Disorders • Dementia

Safety of live-attenuated MMR vaccination in patients with multiple myeloma receiving daratumumab after autologous stem cell transplantation (ASH 2025) - "The majority of patients (59%) received daratumumabin combination with lenalidomide (52%) or pomalidomide (7%) and dexamethasone, with remainingpatients receiving in combination with a proteasome inhibitor (7%) or as monotherapy (34%)...Our findings suggest MMR vaccination in immunocompromised patients with myeloma receivingdaratumumab after ASCT appears to be safe. Though a limited sample size, we did not observe anyvaccine-related disseminated measles, mumps, or rubella infections post-vaccination. MMR vaccination isespecially important for these immunocompromised patients given the rising rates of vaccine hesitancyin the general population and the increase in confirmed measles cases in the United States during 2024and 2025."

Clinical • Dermatology • Hematological Malignancies • Infectious Disease • Measles • Multiple Myeloma • Mumps • Musculoskeletal Pain • Otorhinolaryngology • Respiratory Diseases • Rubella • Sinusitis • Transplantation

A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (clinicaltrials.gov) - P3 | N=2440 | Recruiting | Sponsor: Sanofi | Trial completion date: Oct 2029 ➔ Mar 2030

Trial completion date • Pediatrics

Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort. (PubMed, Brain Commun) - "All plasma biomarkers correlated significantly with their CSF counterpart. These findings reinforce the utility of plasma biomarkers, particularly pTau-217, as indicators of neurodegenerative processes, even in asymptomatic individuals."

Biomarker • Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Diabetes • Dyslipidemia • Hypertension • Inflammation • Metabolic Disorders • Aβ42 • GFAP • NEFL

Advances in Proximity-Assisted Bioconjugation. (PubMed, Acc Chem Res) - "Here, we discovered the secondary participation of proximal lysines on Trastuzumab-V205C and Gemtuzumab-V205C, conjugatable THIOMAB antibodies commonly used in ADCs, leading to the formation of distinct bioconjugate products relative to IgGs without such lysines...In short, this Account highlights our group's contributions to and insights on PAB methodologies wherein we illustrate how PIC can be thoughtfully applied to bioconjugation techniques for various aims including regioselective bioconjugation and enhanced bioconjugate stability. We expect that PAB approaches will continue to diversify bioconjugation applications and greatly expand the toolkit of chemical biologists."

Journal

A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (clinicaltrials.gov) - P3 | N=2440 | Recruiting | Sponsor: Sanofi

New P3 trial • Pediatrics

Cognitive Outcomes and Quality of Life in Stable Renal Transplant Patients Switched from Twice-Daily Tacrolimus to Envarsus XRTM (WTC 2025) - "Kidney transplant patients converted from IR tacrolimus to LCP-Tacro led to statistically significant benefits in cognitive function including visual attention, executive functioning, and memory."

Clinical • HEOR • Late-breaking abstract • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Insomnia • Movement Disorders • Post-traumatic Stress Disorder • Sleep Disorder • Solid Tumor • Transplantation

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Trial completion date: May 2027 ➔ Aug 2027 | Trial primary completion date: May 2027 ➔ Aug 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

In brief: Prevention of measles. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Infectious Disease • Measles

Network localization of regional homogeneity alterations in Parkinson's disease. (PubMed, Front Aging Neurosci) - "This network-centric view offers a unifying perspective on PD pathophysiology, highlighting large-scale systems disruption and potentially reconciling previous localization inconsistencies. This approach underscores the value of network neuroscience for understanding PD mechanisms."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Prediction of clinical pregnancy after frozen embryo transfer based on ultrasound radiomics: an analysis based on the optimal periendometrial zone. (PubMed, BMC Pregnancy Childbirth) - "PEZ4.0 mm could be the optimal area for predicting clinical pregnancy after FET. An US-based radiomics model that combines EN and PEZ4.0 mm demonstrated strong potential in helping clinicians predict FET outcomes more accurately, thereby supporting informed decision-making before treatment."

Journal

Neuropsychological Profile in Adults with Asymptomatic, Untreated Congenital Hydrocephalus (AAN 2025) - "The results suggest that healthy neurologically normal adults with asymptomatic UCH may have mild cognitive weaknesses in areas of psychomotor processing, mental tracking/sequencing, and contextual learning and memory, even in the absence of cerebral microvascular disease. It is unclear whether these deficits are developmental and longstanding, or represent a decline from previous functioning. Longitudinal studies of asymptomatic adults with UCH are needed."

Clinical • CNS Disorders • Cognitive Disorders • Vascular Neurology • Ventriculomegaly

Comparison of Eligibility Criteria and Baseline Characteristics Between the Patient Populations of evoke and evoke+, Clarity AD and TRAILBLAZER-ALZ-2 (AAN 2025) - "Objective:To compare the evoke and evoke+ trial populations with other phase 3 programs for disease-modifying therapy (DMT) in early Alzheimer's disease (AD).Background:evoke and evoke+ are phase 3, randomized, placebo-controlled trials currently investigating the glucagon-like peptide-1 receptor agonist semaglutide DMT in persons with early AD.Design/We compared the inclusion/exclusion criteria and baseline characteristics of the evoke/evoke+ trial populations with those of Clarity AD (lecanemab) and TRAILBLAZER-ALZ-2 (donanemab): two recent phase 3 trials assessing anti-amyloid monoclonal antibodies in persons with early AD...All four studies targeted biologically defined early-stage AD but differed in cognitive inclusion criteria. Unlike evoke/evoke+ and Clarity AD, TRAILBLAZER-ALZ-2 recruited more patients with impairment and used tau PET for staging. A higher number of non-White participants were included in evoke, evoke+ and Clarity AD vs TRAILBLAZER-ALZ-2."

Clinical • Alzheimer's Disease • CNS Disorders

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Tablet-based self assessment memory scale-revised (SAMS-R) evaluates memory functions for older adults. (PubMed, Front Aging Neurosci) - "The ROC curve analysis was conducted to evaluate the detectability to determine whether if the WMS-R LM II score is above or below 10, showing that the AUC was greater than 0.9. SAMS-R, which can be performed on a tablet literally by himself/herself independently, shows a high correlation with the WMS-R Logical Memory II score, and has the advantage of being performed in a short time without the need for a clinical psychologist or other personnel."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (clinicaltrials.gov) - P3 | N=1196 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed | Trial completion date: May 2025 ➔ Dec 2024

Trial completion • Trial completion date • Infectious Disease • Meningococcal Infections • Pneumococcal Infections

CORAL: Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (clinicaltrials.gov) - P3 | N=2226 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Drug Development. (PubMed, Alzheimers Dement) - "All four studies targeted biologically defined early-stage AD patients but differed in cognitive inclusion criteria. TRAILBLAZER-ALZ-2 differed from evoke, evoke+ and Clarity AD in having more impaired patients and using tau PET for staging. A higher number of non-White participants were included in evoke, evoke+ and Clarity AD vs TRAILBLAZER-ALZ-2. Data for evoke and evoke+ are still subject to cleaning."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia